[1] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol, 2020; 76, 2982−3021. doi:  10.1016/j.jacc.2020.11.010
[2] GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020; 396, 1223−49. doi:  10.1016/S0140-6736(20)30752-2
[3] Aulin J, Siegbahn A, Hijazi Z, et al. Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation. Am Heart J, 2015; 170, 1151−60. doi:  10.1016/j.ahj.2015.09.018
[4] Davidson MH, Corson MA, Alberts MJ, et al. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol, 2008; 101, 51F−7F. doi:  10.1016/j.amjcard.2008.04.019
[5] Mani P, Puri R, Schwartz GG, et al. Association of initial and serial C-reactive protein levels with adverse cardiovascular events and death after acute coronary syndrome: a secondary analysis of the VISTA-16 trial. JAMA Cardiol, 2019; 4, 314−20. doi:  10.1001/jamacardio.2019.0179
[6] Veeranna V, Zalawadiya SK, Niraj A, et al. Homocysteine and reclassification of cardiovascular disease risk. J Am Coll Cardiol, 2011; 58, 1025−33. doi:  10.1016/j.jacc.2011.05.028
[7] Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol, 2006; 26, 2523−9. doi:  10.1161/01.ATV.0000244681.72738.bc
[8] Vittos O, Toana B, Vittos A, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2): A review of its role and significance as a cardiovascular biomarker. Biomarkers, 2012; 17, 289−302. doi:  10.3109/1354750X.2012.664170
[9] Zhang H, Gao Y, Wu D, et al. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease. BMC Cardiovasc Disord, 2020; 20, 295. doi:  10.1186/s12872-020-01580-4
[10] Sheng GH, Zhou J, Chang C, et al. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study. Scott Med J, 2021; 66, 178−85. doi:  10.1177/00369330211034809
[11] Lee KK, Fortmann SP, Varady A, et al. Racial variation in lipoprotein-associated phospholipase A2 in older adults. BMC Cardiovasc Disord, 2021; 11, 38.
[12] Brilakis ES, Khera A, Mcguire DK, et al. Influence of race and sex on lipoprotein- associated phospholipase A2 levels: observations from the Dallas heart study. Atherosclerosis, 2008; 199, 110−5. doi:  10.1016/j.atherosclerosis.2007.10.010
[13] Wu SL, Huang ZR, Yang XC, et al. Prevalence of ideal cardiovascular health and its relationship with the 4-year cardiovascular events in a Northern Chinese industrial city. Circ Cardiovasc Qual Outcomes, 2012; 5, 487−93. doi:  10.1161/CIRCOUTCOMES.111.963694
[14] Zhou Y, Li Y, Xu L, et al. Asymptomatic Polyvascular Abnormalities in Community (APAC) study in China: objectives, design and baseline characteristics. PLoS One, 2013; 8, e84685. doi:  10.1371/journal.pone.0084685
[15] Song DY, Wang XW, Wang S, et al. Jidong cognitive impairment cohort study: objectives, design, and baseline screening. Neural Regen Res, 2020; 15, 1111−9. doi:  10.4103/1673-5374.266070
[16] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA, 2001; 285, 2486−97. doi:  10.1001/jama.285.19.2486
[17] Qiu MS, Wang XW, Yao Y, et al. Protocol of Jidong women health cohort study: rationale, design, and baseline characteristics. Biomed Environ Sci, 2019; 32, 144−52.
[18] Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association. Circulation, 2003; 107, 499−511. doi:  10.1161/01.CIR.0000052939.59093.45
[19] World Health Organization. Stroke—1989 recommendations on stroke prevention, diagnosis, and therapy report of the WHO task force on stroke and other cerebrovascular disorders. Stroke, 1989; 20, 1407−31. doi:  10.1161/01.STR.20.10.1407
[20] Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. J Am Coll Cardiol, 2007; 50, 2173−95. doi:  10.1016/j.jacc.2007.09.011
[21] Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the atherosclerosis risk in Communities (ARIC) study. Circulation, 2004; 109, 837−42. doi:  10.1161/01.CIR.0000116763.91992.F1
[22] Oei HHS, Van Der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam study. Circulation, 2005; 111, 570−5. doi:  10.1161/01.CIR.0000154553.12214.CD
[23] Sudhir K. Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab, 2005; 90, 3100−5. doi:  10.1210/jc.2004-2027
[24] Garg PK, McClelland RL, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: the multi ethnic study of atherosclerosis. Atherosclerosis, 2015; 241, 176−82. doi:  10.1016/j.atherosclerosis.2015.05.006
[25] Zhang FJ, Guo JW, Yang FF, et al. Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations. J Clin Lab Anal, 2011; 35, e23691.
[26] Jenny NS, Solomon C, Cushman M, et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) and risk of cardiovascular disease in older adults: results from the cardiovascular health study. Atherosclerosis, 2010; 209, 528−32. doi:  10.1016/j.atherosclerosis.2009.09.021
[27] Wang YX, Zhou B, Zhou PG, et al. Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis. J Cell Mol Med, 2018; 22, 2329−36. doi:  10.1111/jcmm.13521
[28] Daniels LB, Laughlin GA, Sarno MJ, et al. Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the rancho Bernardo study. J Am Coll Cardiol, 2008; 51, 913−9. doi:  10.1016/j.jacc.2007.10.048
[29] Brilakis ES, Khera A, Saeed B, et al. Association of lipoprotein-associated phospholipase A2 mass and activity with coronary and aortic atherosclerosis: findings from the Dallas heart study. Clin Chem, 2008; 54, 1975−81. doi:  10.1373/clinchem.2008.107359
[30] Miyaura S, Maki N, Byrd W, et al. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids, 1991; 26, 1015−20. doi:  10.1007/BF02536494
[31] Liu HM, Yao Y, Wang YX, et al. Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: A cross-sectional study. J Cell Mol Med, 2018; 22, 5145−50. doi:  10.1111/jcmm.13803
[32] Jellinger PS, Handelsman Y, Rosenblit PD, et al. American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract, 2017; 23, 479−97. doi:  10.4158/EP171764.GL
[33] Anuurad E, Ozturk Z, Enkhmaa B, et al. Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and Caucasians. J Clin Endocrinol Metab, 2010; 95, 2376−83. doi:  10.1210/jc.2009-2498
[34] The Lp-PLA2 Studies Collaboration. Collaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil, 2007; 14, 3−11. doi:  10.1097/01.hjr.0000239464.18509.f1
[35] Lin YH, Gong ML, Zhang P, et al. Establishment of normal reference interval of lipoprotein-associated phospholipase A2 quality concentration in apparent healthy people aged over 50 years. Chin J Lab Med, 2021; 32−8. (In Chinese
[36] Ueshima H, Kadowaki T, Hisamatsu T, et al. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis, 2016; 246, 141−7. doi:  10.1016/j.atherosclerosis.2015.12.027